AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial

AbbVie’s recently acquired Parkinson’s disease candidate tavapadon significantly reduced the burden of disease in a Phase III trial.

The Phase III TEMPO-1 trial (NCT04201093) evaluated two daily doses of tavapadon (5mg and 15mg). The trial met its primary endpoint, with both dose groups outperforming placebo in improving disease burden at week 26, as measured by a combined score from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).